Perrigo Company (PRGO) reported first quarter fiscal 2011 EPS of $0.87, well above the Zacks Consensus Estimate of $0.77. We believe that Perrigo's strong position in the brand OTC pharmaceutical market and growing generics and API businesses will help it deliver solid top- and bottom-line growth in the coming years.
Market News and Data brought to you by Benzinga APIsWe also expect the company to benefit from OTC switches from branded products in the next five years. Moreover, management's policy of pursuing on smart strategic deals will continue to drive growth for the company.
Perrigo also has a very strong and impressive pipeline. We, therefore, initiate coverage on the stock with an Outperform rating.
PERRIGO COMPANY (PRGO): Free Stock Analysis Report
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Health CarePharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in